Datametrex Secures Rights To Sell And Distribute Rapid COVID-19 Antigen Test Kits

Datametrex AI (TSXV: DM) this morning announced that it has secured the rights to sell and distribute a rapid antigen detection kit from South Korean manufacturer PCL Inc. The main benefit of the test is that with 97% accuracy, they produce results in as little as 5 to 10 minutes with no extra equipment being required for the consumer.

Datametrex AI's Logo

The test hosts advantages over others on the market solely as a result of the rapid testing nature of the product, combined with the lack of additional equipment being needed to conduct the test. The test is a method of measuring the presence of a COVID-19 infection via an in-vitro diagnostic medical device. It detects antigen of the SARS-CoV-2 virus from a persons oropharyngeal and nasopharyngeal secretions. Like a simple pregnancy test, if antigens are found a colored line appears in the T line area.

It’s said that the test has a clinical sensitivity, i.e., the ability to confirm the actual positive of the approved person, of 100%, and the clinical specificity, i.e the ability to confirm the actual negative of the negative person, of 97.78%. The antigen test has been awarded numerous certifications, including CE, Korea FDA, UNGM and more. It’s also been approved by the EU, Qatar, United Arab Emirates, India, Russia, Ecuador, Guatemala and Colombia.

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy. These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

Marshall Gunter, CEO of Datametrex

The strong benefit of the instant antigen kits that require no additional equipment, is that they can be conducted at home easily, with nearly instant results. This eliminates excessive wait times as high as 3-5 days or more previously experienced by individuals that have had other forms of COVID-19 tests performed.

Datametrex AI last traded at $0.15 on the TSX Venture.


FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Recommended

Total Metals Secures High Grade Critical Minerals Property In Northwestern Ontario

Discovery at Luis Hill Prompts Acceleration of Phase 2 Program for Questcorp

Related News

Datametrex AI Secures Two Additional Testing Contracts In Film Industry

Datametrex AI (TSXV: DM) continues to deliver on its healthcare operation as it pertains to...

Monday, August 30, 2021, 09:58:00 AM

Datametrex Launches Nexalogy SMART AI-Based Technology

Datametrex AI Limited (TSXV: DM) subsidiary Nexalogy has launched its Social Media Automated Reporting Technologies...

Wednesday, December 9, 2020, 03:26:00 PM

Venezuela Experiencing Protests and Looting Amid Food and Fuel Shortages

Although North America is experiencing an oversupply of fossil fuels and bottle-necked food chains amid...

Tuesday, April 28, 2020, 08:40:57 AM

JPMorgan and World Bank Make Grim Economic Predictions Amid Coronavirus Pandemic

Several economic reports from both JPMorgan and the World Bank have recently been released, providing...

Tuesday, April 14, 2020, 11:12:54 AM

Goldman Expecting Global Oil Storage to Reach Capacity in Coming Weeks

As previously reported, it is anticipated that US oil storage will reach maximum capacity by...

Sunday, April 26, 2020, 12:00:00 PM